Posted by Michael Wonder on 07 Dec 2021
Daré announces FDA approval of Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis
7 December 2021 - Prescribing information supports positioning of Xaciato as a first line option for the treatment of bacterial vaginosis.
Daré Bioscience today announced that the U.S. FDA approved Xaciato (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.
